The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase

被引:147
作者
Raveh, L
Grauer, E
Grunwald, J
Cohen, E
Ashani, Y
机构
[1] ISRAEL INST BIOL RES,NESS ZIONA,ISRAEL
[2] HEBREW UNIV JERUSALEM,FAC AGR,IL-76100 REHOVOT,ISRAEL
关键词
D O I
10.1006/taap.1997.8160
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bioscavengers of organophophates (OF) have been examined as potential substitutes for the currently approved drug treatment against OP toxicity. The present work was designed to assess the ability of butyrylcholinesterase, purified from human serum (HuBChE), to prevent the toxicity induced by soman and VX in rhesus monkeys. The consistency of the data across species was then evaluated as the basis for the extrapolation of the data to humans. The average mean residence time of the enzyme in the circulation of monkeys following an intravenous loading was 34 hr. High bioavailability of HuBChE in blood (>80%) was demonstrated after intramuscular injection. A molar ratio of HuBChE:OP similar to 1.2 protected against an iv bolus injection of 2.1 x LD50 VX, while a ratio of 0.62 was sufficient to protect monkeys against an iv dose of 3.3 x LD50 of soman, with no additional postexposure therapy. A remarkable protection was also seen against soman-induced behavioral deficits detected in the performance of a spatial discrimination task. The consistency of the results across several species offers a reliable prediction of both the stoichiometry of the scavenging and the extent of prophylaxis with HuBChE against nerve agent toxicity in humans. (C) 1997 Academic Press.
引用
收藏
页码:43 / 53
页数:11
相关论文
共 37 条
[1]   BUTYRYLCHOLINESTERASE AND ACETYLCHOLINESTERASE PROPHYLAXIS AGAINST SOMAN POISONING IN MICE [J].
ASHANI, Y ;
SHAPIRA, S ;
LEVY, D ;
WOLFE, AD ;
DOCTOR, BP ;
RAVEH, L .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (01) :37-41
[2]   TOXICOKINETICS OF SOMAN - SPECIES VARIATION AND STEREOSPECIFICITY IN ELIMINATION PATHWAYS [J].
BENSCHOP, HP ;
DEJONG, LPA .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1991, 15 (01) :73-77
[3]   ACUTE BEHAVIORAL TOXICITY OF PYRIDOSTIGMINE OR SOMAN IN PRIMATES [J].
BLICK, DW ;
MURPHY, MR ;
BROWN, GC ;
YOCHMOWITZ, MG ;
FANTON, JW ;
HARTGRAVES, SL .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 126 (02) :311-318
[4]   PREVENTION OF SOMAN-INDUCED COGNITIVE DEFICITS BY PRETREATMENT WITH HUMAN BUTYRYLCHOLINESTERASE IN RATS [J].
BRANDEIS, R ;
RAVEH, L ;
GRUNWALD, J ;
COHEN, E ;
ASHANI, Y .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 46 (04) :889-896
[5]  
BROOMFIELD CA, 1991, J PHARMACOL EXP THER, V259, P633
[6]  
Cascio C, 1988, Minerva Anestesiol, V54, P337
[7]  
CASTRO CA, 1994, NEUROTOXICOL TERATOL, V16, P45
[8]  
Castro CA, 1991, PHARM BIOCH BEHAV, V41, P159
[9]   PROTECTION OF PRIMATES AGAINST SOMAN POISONING BY PRETREATMENT WITH PYRIDOSTIGMINE [J].
DIRNHUBER, P ;
FRENCH, MC ;
GREEN, DM ;
LEADBEATER, L ;
STRATTON, JA .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (05) :295-299
[10]   BEHAVIORAL TOXICITY OF ANTICHOLINESTERASES IN HUMANS AND ANIMALS - A REVIEW [J].
DMELLO, GD .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1993, 12 (01) :3-7